0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Electrophilic proximity-inducing synthetic adapters enhance universal T cell function by covalently enforcing immune receptor signaling

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Proximity-induction of cell-cell interactions via small molecules represents an emerging field in basic and translational sciences. Covalent anchoring of these small molecules represents a useful chemical strategy to enforce proximity; however, it remains largely unexplored for driving cell-cell interactions. In immunotherapeutic applications, bifunctional small molecules are attractive tools for inducing proximity between immune effector cells like T cells and tumor cells to induce tumoricidal function. We describe a two-component system composed of electrophilic bifunctional small molecules and paired synthetic antigen receptors (SARs) that elicit T cell activation. The molecules, termed covalent immune recruiters (CIRs), were designed to affinity label and covalently engage SARs. We evaluated the utility of CIRs to direct anti-tumor function of human T cells engineered with three biologically distinct classes of SAR. Irrespective of the electrophilic chemistry, tumor-targeting moiety, or SAR design, CIRs outperformed equivalent non-covalent bifunctional adapters, establishing a key role for covalency in maximizing functionality. We determined that covalent linkage enforced early T cell activation events in a manner that was dependent upon each SARs biology and signaling threshold. These results provide a platform to optimize universal SAR-T cell functionality and more broadly reveal new insights into how covalent adapters modulate cell-cell proximity-induction.

          Graphical abstract

          Abstract

          Serniuck and colleagues have shown that bifunctional small molecules capable of affinity-induced covalent labeling of synthetic antigen receptors can greatly enhance the anti-tumor activity of human T cells. This synthetic design is amenable to any targeting ligand, making this technology broadly applicable to all universal receptor platforms.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          Fiji: an open-source platform for biological-image analysis.

          Fiji is a distribution of the popular open-source software ImageJ focused on biological-image analysis. Fiji uses modern software engineering practices to combine powerful software libraries with a broad range of scripting languages to enable rapid prototyping of image-processing algorithms. Fiji facilitates the transformation of new algorithms into ImageJ plugins that can be shared with end users through an integrated update system. We propose Fiji as a platform for productive collaboration between computer science and biology research communities.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            QuPath: Open source software for digital pathology image analysis

            QuPath is new bioimage analysis software designed to meet the growing need for a user-friendly, extensible, open-source solution for digital pathology and whole slide image analysis. In addition to offering a comprehensive panel of tumor identification and high-throughput biomarker evaluation tools, QuPath provides researchers with powerful batch-processing and scripting functionality, and an extensible platform with which to develop and share new algorithms to analyze complex tissue images. Furthermore, QuPath’s flexible design makes it suitable for a wide range of additional image analysis applications across biomedical research.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Chimeric antigen receptor T cells for sustained remissions in leukemia.

              Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease. We infused autologous T cells transduced with a CD19-directed chimeric antigen receptor (CTL019) lentiviral vector in patients with relapsed or refractory ALL at doses of 0.76×10(6) to 20.6×10(6) CTL019 cells per kilogram of body weight. Patients were monitored for a response, toxic effects, and the expansion and persistence of circulating CTL019 T cells. A total of 30 children and adults received CTL019. Complete remission was achieved in 27 patients (90%), including 2 patients with blinatumomab-refractory disease and 15 who had undergone stem-cell transplantation. CTL019 cells proliferated in vivo and were detectable in the blood, bone marrow, and cerebrospinal fluid of patients who had a response. Sustained remission was achieved with a 6-month event-free survival rate of 67% (95% confidence interval [CI], 51 to 88) and an overall survival rate of 78% (95% CI, 65 to 95). At 6 months, the probability that a patient would have persistence of CTL019 was 68% (95% CI, 50 to 92) and the probability that a patient would have relapse-free B-cell aplasia was 73% (95% CI, 57 to 94). All the patients had the cytokine-release syndrome. Severe cytokine-release syndrome, which developed in 27% of the patients, was associated with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab. Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed. (Funded by Novartis and others; CART19 ClinicalTrials.gov numbers, NCT01626495 and NCT01029366.).
                Bookmark

                Author and article information

                Contributors
                Journal
                Mol Ther Oncol
                Mol Ther Oncol
                Molecular Therapy Oncology
                American Society of Gene & Cell Therapy
                2950-3299
                24 June 2024
                19 September 2024
                24 June 2024
                : 32
                : 3
                : 200842
                Affiliations
                [1 ]Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada
                [2 ]McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada
                [3 ]Department of Medicine, McMaster University, Hamilton, ON, Canada
                [4 ]Department of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada
                Author notes
                []Corresponding author: Jonathan L. Bramson, Office of the Vice Dean Research, Faculty of Health Sciences, McMaster University, HSC 2E17, 1280 Main St West, Hamilton, ON L8S 4K1, Canada. bramsonj@ 123456mcmaster.ca
                [∗∗ ]Corresponding author: Anthony Rullo, McMaster University, MDCL 4015, 1280 Main St West, Hamilton, ON L8S 4K1, Canada. rulloa@ 123456mcmaster.ca
                Article
                S2950-3299(24)00084-5 200842
                10.1016/j.omton.2024.200842
                11264187
                39045028
                df17083f-0952-4071-8904-532bac101020
                © 2024 The Authors

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 18 April 2024
                : 10 June 2024
                : 21 June 2024
                Categories
                Original Article

                mt: regular issue,covalent bifunctional adapters,proximity induced labeling,chemical/synthetic immunotherapy,engineered t cells,universal synthetic antigen receptors

                Comments

                Comment on this article